VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.

Saved in:
Bibliographic Details
Title: VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
Authors: Setty BA; Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio., Stanek JR; Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio., Mascarenhas L; Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California.; Keck School of Medicine, University of Southern California, Los Angeles, California., Miller A; Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Bagatell R; Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Okcu F; Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas., Nicholls L; Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas., Lysecki D; Division of Pediatrics, McMaster Children's Hospital, Hamilton, Ontario, Canada., Gupta AA; Department of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Source: Pediatric blood & cancer [Pediatr Blood Cancer] 2018 Jan; Vol. 65 (1). Date of Electronic Publication: 2017 Jul 27.
Publication Type: Clinical Trial; Journal Article; Multicenter Study
Journal Info: Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1545-5017
DOI:10.1002/pbc.26728